At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 7 enrolled
Drug / intervention
EVLP Groupprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ex-Vivo Lung Perfusion to Improve Donor Lung Function and Increase the Number of Organs Available for Transplantation
In Brief
A Phase 1 clinical trial evaluating EVLP Group for Disorder Related to Lung Transplantation and 3 related conditions. Completed, enrolled 7 participants across 1 site.
Detailed Summary
The recent introduction of ex-vivo lung perfusion (EVLP) as a tool to evaluate and recondition lungs from marginal donors has opened a new era in the field of lung transplantation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDisorder Related to Lung Transplantation, Brain Death, Graft Failure, Primary Graft Dysfunction
CountriesItaly
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
Primary CompletionMay 2013
First PostedOct 2013
TodayJul 2026
First PostedOct 23, 2013
Enrollment StartJan 1, 2011
Primary CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 12.7 years ago
Interventions
EVLP Groupprocedure
EVLP technique: Steen solution; normothermia; low flow, open atrium, low hematocrit. Endpoints of EVLP assessment of lungs suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy